Germany plans to apply to host the London-based European Medicines Agency and the European Banking Authority after Britain leaves the European Union, Reuters reported. “Germany is throwing its hat into the ring for both agencies – with Bonn for the European Medicines Agency EMA and with Frankfurt for the European Banking Authority EBA,” government spokesman Steffen Seibert […]
Pharmaceuticals
Johnson & Johnson wins last regulatory nod needed for Actelion acquisition
Johnson & Johnson (NYSE:JNJ) said today that the European Commission approved its acquisition of Swiss biotech Actelion. The regulatory nod was the last approval needed to complete the company’s transaction. The U.S. healthcare giant added that it expects the settlement of the $30 billion all-cash tender offer on June 16. The EU commission set conditions […]
Magnets, nanoparticles open and close blood vessels for targeted drug delivery
Tightly-packed endothelial cells line blood vessels and maintain a highly structured barrier. But researchers from Rice University, Emory University and the Georgia Institute of Technology have found a way to selectively create “leaky” blood vessels for targeted drug delivery. The team’s study, which was published in Nature Communications, reported that magnets can help lead iron-oxide nanoparticles […]
FDA asks Endo to pull Opana from the market over concerns of abuse
The FDA asked Endo Pharmaceuticals (NSDQ:ENDP) to pull its opioid pain med, Opana ER, from the market, saying that the benefits of the abuse-deterrent drug no longer outweigh the risks. The move marks the 1st time the federal regulatory watchdog has urged a company to remove an opioid painkiller due to concerns of abuse. “We are facing […]
Glytec, AgaMatrix ink deal to develop digital diabetes management platform
AgaMatrix and Glytec said today that the companies are partnering to develop a cloud-based diabetes management platform to optimize clinical access to glucose data and insulin titration support. The platform will combine AgaMatrix’s FDA-cleared Jazz Wireless 2 Bluetooth blood glucose monitoring tech with Glytec’s eGlycemic Management System, according to the companies. The companies are developing […]
Bigfoot buys connected insulin pen tech
Artificial pancreas developer Bigfoot Biomedical said today that it acquired Patients Pending and its connected insulin pen technology for an undisclosed amount. With this acquisition, Bigfoot said it is the 1st company to simultaneously pursue both insulin infusion and injection delivery solutions. “Bigfoot isn’t in the pump business. And even though we are excited to […]
Mylan defends chairman to shareholder advisory firm amid scrutiny
Mylan (NSDQ:MYL) defended chairman Robert Coury to Institutional Shareholder Services, an shareholder advisory group, earlier this week as the firm prepares to release a report advising shareholders how they should vote in the upcoming re-election of Coury and other directors. Major investors like the New York City and State pension funds have urged shareholders to vote against […]
Clearside Biomedical highlights preliminary data from retreatment trial
Clearside Biomedical (NSDQ:CLSD) touted preliminary data from a non-interventional and retrospective trial of patients who participated in the completed Phase II trial of CLS-TA for suprachoroidal administration. Clearside’s formulation of triamcinolone acetonide, in combination with intravitreally administered Eylea, was evaluated as a treatment for macular edema associated with retinal vein occlusion. The company’s Phase II […]
Novocure launches Optune, chemotherapy combo trial for glioblastoma
Novocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma. In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients […]
InCarda touts inhaled flecainide as paroxysmal atrial fibrillation therapy
InCarda Therapeutics touted top-line data today from a Phase I study of its InRhythm inhaled flecainide as a treatment of symptomatic acute episodes of paroxysmal atrial fibrillation. InRhythm delivers flecainide via inhalation to get the drug to the heart through the lungs. Flecainide is already approved as an oral anti-arrhythmic drug for patients with PAF. […]